目的:研究维格列净口服溶液作为初治和先前胰岛素治疗的糖尿病猫的唯一治疗的安全性和有效性。
方法:252只接受≥2剂velagliflozin的客户拥有的猫;214例(85%)初治糖尿病患者和38例(15%)胰岛素治疗的糖尿病患者。
方法:前瞻性,基线控制,开放标签临床现场试验。猫口服velagliflozin,每天一次。在第0、3、7、30、60、120和180天进行体格检查和采血。
结果:数据是中位数(范围)。筛查血糖(BG)为436mg/dL(272~676mg/dL)。在第30、60、120和180天,接受维格列净后的单个BG为153mg/dL(62至480mg/dL),134mg/dL(64至414mg/dL),128mg/dL(55至461mg/dL),和125毫克/分升(77至384毫克/分升),分别。筛选果糖胺为538μmol/L(375至794μmol/L)。在同样的复查日,果糖胺为310μmol/L(204至609μmol/L),286μmol/L(175至531μmol/L),269µmol/L(189至575µmol/L),和263μmol/L(203至620μmol/L)。在第180天,剩下的158只猫中,有81%的BG和/或果糖胺在参考范围内;88.6%(140中的124)和87.7%(138中的121)显示多尿和多饮改善,分别。Ketonuria在35只猫中发展(13.9%),其中18例(7.1%)有酮症酸中毒。与胰岛素治疗的糖尿病猫(38只中的7只[18.4%])相比,酮症酸中毒在初治糖尿病猫中较不常见(214只中的11只[5.1%])。在酮症酸中毒诊断时,18只猫中有14只(77.8%)是正常血糖的(即,BG<250mg/dL)。大多数酮症或酮症酸中毒发作(35例中的30例[85.7%])发生在治疗的前14天内。胰岛素治疗的糖尿病猫不太可能完成试验。无临床低血糖发生。
结论:Velagliflozin改善了糖尿病猫的血糖参数和临床体征。Velagliflozin作为糖尿病猫的独立治疗提供了胰岛素的替代品。
OBJECTIVE: To investigate safety and effectiveness of velagliflozin oral solution as sole therapy in naïve and previously insulin-treated diabetic cats.
METHODS: 252 client-owned cats receiving ≥ 2 doses of velagliflozin; 214 (85%) naïve diabetics and 38 (15%) insulin-treated diabetics.
METHODS: Prospective, baseline-controlled, open-label clinical field trial. Cats received velagliflozin orally, once daily. Physical examinations and blood collections were performed days 0, 3, 7, 30, 60, 120, and 180.
RESULTS: Data are median (range). Screening blood glucose (BG) was 436 mg/dL (272 to 676 mg/dL). On days 30, 60, 120, and 180, single BG after receiving velagliflozin was 153 mg/dL (62 to 480 mg/dL), 134 mg/dL (64 to 414 mg/dL), 128 mg/dL (55 to 461 mg/dL), and 125 mg/dL (77 to 384 mg/dL), respectively. Screening fructosamine was 538 µmol/L (375 to 794 µmol/L). On the same recheck days, fructosamine was 310 µmol/L (204 to 609 µmol/L), 286 µmol/L (175 to 531 µmol/L), 269 µmol/L (189 to 575 µmol/L), and 263 µmol/L (203 to 620 µmol/L). At day 180, 81% of 158 cats remaining had BG and/or fructosamine within reference ranges; 88.6% (124 of 140) and 87.7% (121 of 138) showed improvement in polyuria and polydipsia, respectively. Ketonuria developed in 35 cats (13.9%), including 18 (7.1%) that had ketoacidosis. Ketoacidosis was less common in naïve diabetic cats (11 of 214 [5.1%]) compared to insulin-treated diabetic cats (7 of 38 [18.4%]). At ketoacidosis diagnosis, 14 of 18 cats (77.8%) were euglycemic (ie, BG < 250 mg/dL). Most episodes of ketosis or ketoacidosis (30 of 35 [85.7%]) occurred within the first 14 days of treatment. Insulin-treated diabetic cats were less likely to complete the trial. No clinical hypoglycemia occurred.
CONCLUSIONS: Velagliflozin improved glycemic parameters and clinical signs in diabetic cats. Velagliflozin provides an alternative to insulin as a stand-alone treatment of diabetic cats.